Selective neuroprotective effects of the S18Y polymorphic variant of UCH-L1 in the dopaminergic system

Human Molecular Genetics

Volumn 21, Issue 4, 2012, Pages 874-889

  Xilouri, Maria ^a   Kyratzi, Elli ^a   Pitychoutis, Pothitos M ^b   Papadopoulou Daifoti, Zoi ^b   Perier, Celine ^c   Vila, Miquel ^c,d,e   Maniati, Matina ^a   Ulusoy, Ayse ^f   Kirik, Deniz ^f   Park, David S ^g   Wada, Keiji ^h   Stefanis, Leonidas ^a,b  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f LUND UNIVERSITY   (Sweden)

^g UNIVERSITY OF OTTAWA   (Canada)

^h NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOVIRUS VECTOR; BETA ACTIN; DOPAMINE; GREEN FLUORESCENT PROTEIN; TYROSINE 3 MONOOXYGENASE; UBIQUITIN THIOLESTERASE; UBIQUITIN THIOLESTERASE L1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; GENETIC POLYMORPHISM; IN VIVO STUDY; MALE; MOUSE; NERVE DEGENERATION; NEUROAXONAL DYSTROPHY; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADENOVIRIDAE; ANIMALS; ANTIOXIDANTS; CELL DEATH; DOPAMINE; DOPAMINERGIC NEURONS; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NEOSTRIATUM; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; POLYMORPHISM, GENETIC; UBIQUITIN THIOLESTERASE;

MUS;

EID: 84856347615     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr521     Document Type: Article

References (66)

1. Wilkinson, K.D., Lee, K.M., Deshpande, S., Duerksen-Hughes, P., Boss, J.M. and Pohl, J. (1989) The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science, 246, 670-673.
2. Nijman, S.M., Luna-Vargas, M.P., Velds, A., Brummelkamp, T.R., Dirac, A.M., Sixma, T.K. and Bernards, R. (2005) A genomic and functional inventory of deubiquitinating enzymes. Cell, 123, 773-786.
3. Setsuie, R. and Wada, K. (2007) The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem. Int., 51, 105-111.
4. Saigoh, K., Wang, Y.L., Suh, J.G., Yamanishi, T., Sakai, Y., Kiyosawa, H., Harada, T., Ichihara, N., Wakana, S., Kikuchi, T. et al. (1999) Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat. Genet., 23, 47-51.
5. Chen, F., Sugiura, Y., Myers, K.G., Liu, Y. and Lin, W. (2010) Ubiquitin carboxyl-terminal hydrolase L1 is required for maintaining the structure and function of the neuromuscular junction. Proc. Natl Acad. Sci. USA, 107, 1636-1641.
6. Gasser, T. (2009) Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev. Mol. Med., 11, e22.
7. Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M.J., Jonnalagada, S., Chernova, T. et al. (1998) The ubiquitin pathway in Parkinson's disease. Nature, 395, 451-452.
8. Maraganore, D.M., Farrer, M.J., Hardy, J.A., Lincoln, S.J., McDonnell, S.K. and Rocca, W.A. (1999) Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology, 53, 1858-1860.
9. Maraganore, D.M., Lesnick, T.G., Elbaz, A., Chartier-Harlin, M.C., Gasser, T., Kruger, R., Hattori, N., Mellick, G.D., Quattrone, A., Satoh, J. et al. (2004) UCHL1 is a Parkinson's disease susceptibility gene. Ann. Neurol., 55, 512-521.
10. Elbaz, A., Levecque, C., Clavel, J., Vidal, J.S., Richard, F., Correze, J.R., Delemotte, B., Amouyel, P., Alperovitch, A., Chartier-Harlin, M.C. et al. (2003) S18Y polymorphism in the UCH-L1 gene and Parkinson's disease: evidence for an age-dependent relationship. Mov. Disord., 18, 130-137.
11. Satoh, J. and Kuroda, Y. (2001) A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population. J. Neurol. Sci., 189, 113-117.
12. Carmine Belin, A., Westerlund, M., Bergman, O., Nissbrandt, H., Lind, C., Sydow, O. and Galter, D. (2007) S18Y in ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) associated with decreased risk of Parkinson's disease in Sweden. Parkinsonism Relat. Disord., 13, 295-298.
13. Healy, D.G., Abou-Sleiman, P.M., Casas, J.P., Ahmadi, K.R., Lynch, T., Gandhi, S., Muqit, M.M., Foltynie, T., Barker, R., Bhatia, K.P. et al.(2006) UCHL-1 is not a Parkinson's disease susceptibility gene. Ann. Neurol., 59, 627-633.
14. Wang, L., Guo, J.F., Nie, L.L., Luo, L., Zuo, X., Shen, L., Jiang, H., Yan, X.X., Xia, K., Pan, Q. et al. (2011) Case-control study of the UCH-L1 S18Y variant in sporadic Parkinson's disease in the Chinese population. J. Clin. Neurosci., 18, 541-544.
15. Wintermeyer, P., Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Berg, D., Becker, G., Leroy, E., Polymeropoulos, M., Berger, K. et al. (2000) Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. Neuroreport, 11, 2079-2082.
16. Levecque, C., Destee, A., Mouroux, V., Becquet, E., Defebvre, L., Amouyel, P. and Chartier-Harlin, M.C. (2001) No genetic association of the ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism with familial Parkinson's disease. J. Neural. Transm., 108, 979-984.
17. Lincoln, S., Vaughan, J., Wood, N., Baker, M., Adamson, J., Gwinn-Hardy, K., Lynch, T., Hardy, J. and Farrer, M. (1999) Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease. Neuroreport, 10, 427-429.
18. Mellick, G.D. and Silburn, P.A. (2000) The ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism does not confer protection against idiopathic Parkinson's disease. Neurosci. Lett., 293, 127-130.
19. Savettieri, G., De Marco, E.V., Civitelli, D., Salemi, G., Nicoletti, G., Annesi, G., Ciro Candiano, I.C. and Quattrone, A. (2001) Lack of association between ubiquitin carboxy-terminal hydrolase L1 gene polymorphism and PD. Neurology, 57, 560-561.
20. Zhang, Z.J., Burgunder, J.M., An, X.K., Wu, Y., Chen, W.J., Zhang, J.H., Wang, Y.C., Xu, Y.M., Gou, Y.R., Yuan, G.G. et al. (2008) Lack of evidence for association of a UCH-L1 S18Y polymorphism with Parkinson's disease in a Han-Chinese population. Neurosci. Lett., 442, 200-202.
21. Tan, E.K., Lu, C.S., Peng, R., Teo, Y.Y., Wu-Chou, Y.H., Chen, R.S., Weng, Y.H., Chen, C.M., Fung, H.C., Tan, L.C. et al. (2009) Analysis of the UCHL1 genetic variant in Parkinson's disease among Chinese. Neurobiol. Aging, 31, 2194-2196.
22. Setsuie, R., Wang, Y.L., Mochizuki, H., Osaka, H., Hayakawa, H., Ichihara, N., Li, H., Furuta, A., Sano, Y., Sun, Y.J. et al. (2007) Dopaminergic neuronal loss in transgenic mice expressing the Parkinson's disease-associated UCH-L1 I93M mutant. Neurochem. Int., 50, 119-129.
23. Liu, Y., Fallon, L., Lashuel, H.A., Liu, Z. and Lansbury, P.T. Jr. (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell, 111, 209-218.
24. Choi, J., Levey, A.I., Weintraub, S.T., Rees, H.D., Gearing, M., Chin, L.S. and Li, L. (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem., 279, 13256-13264.
25. Butterfield, D.A., Gnjec, A., Poon, H.F., Castegna, A., Pierce, W.M., Klein, J.B. and Martins, R.N. (2006) Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J. Alzheimers Dis., 10, 391-397.
26. Goto, A., Wang, Y.L., Kabuta, T., Setsuie, R., Osaka, H., Sawa, A., Ishiura, S. and Wada, K. (2009) Proteomic and histochemical analysis of proteins involved in the dying-back-type of axonal degeneration in the gracile axonal dystrophy (gad) mouse. Neurochem. Int., 54, 330-338.
27. Castegna, A., Thongboonkerd, V., Klein, J., Lynn, B.C., Wang, Y.L., Osaka, H., Wada, K. and Butterfield, D.A. (2004) Proteomic analysis of brain proteins in the gracile axonal dystrophy (gad) mouse, a syndrome that emanates from dysfunctional ubiquitin carboxyl-terminal hydrolase L-1, reveals oxidation of key proteins. J. Neurochem., 88, 1540-1546.
28. Nagamine, S., Kabuta, T., Furuta, A., Yamamoto, K., Takahashi, A. and Wada, K. (2010) Deficiency of ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1) leads to vulnerability to lipid peroxidation. Neurochem. Int., 57, 102-110.
29. Kyratzi, E., Pavlaki, M. and Stefanis, L. (2008) The S18Y polymorphic variant of UCH-L1 confers an antioxidant function to neuronal cells. Hum. Mol. Genet., 17, 2160-2171.
30. Dauer, W. and Przedborski, S. (2003) Parkinson's disease: mechanisms and models. Neuron, 39, 889-909.
31. Innamorato, N.G., Jazwa, A., Rojo, A.I., Garcia, C., Fernandez-Ruiz, J., Grochot-Przeczek, A., Stachurska, A., Jozkowicz, A., Dulak, J. and Cuadrado, A. (2010) Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS One, 5, e11838.
32. Zhou, H. and Beaudet, A.L. (2000) A new vector system with inducible E2a cell line for production of higher titer and safer adenoviral vectors. Virology, 275, 348-357.
33. Kugler, S., Kilic, E. and Bahr, M. (2003) Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area. Gene Ther., 10, 337-347.
34. Smith, P.D., Crocker, S.J., Jackson-Lewis, V., Jordan-Sciutto, K.L., Hayley, S., Mount, M.P., O'Hare, M.J., Callaghan, S., Slack, R.S., Przedborski, S. et al. (2003) Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc. Natl Acad. Sci. USA, 100, 13650-13655.
35. Crocker, S.J., Smith, P.D., Jackson-Lewis, V., Lamba, W.R., Hayley, S.P., Grimm, E., Callaghan, S.M., Slack, R.S., Melloni, E., Przedborski, S. et al. (2003) Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J. Neurosci., 23, 4081-4091.
36. Qu, D., Rashidian, J., Mount, M.P., Aleyasin, H., Parsanejad, M., Lira, A., Haque, E., Zhang, Y., Callaghan, S., Daigle, M. et al. (2007) Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease. Neuron, 55, 37-52.
37. Dusonchet, J., Kochubey, O., Stafa, K., Young, S.M. Jr, Zufferey, R., Moore, D.J., Schneider, B.L. and Aebischer, P. (2011) A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. J. Neurosci., 31, 907-912.
38. Przedborski, S. and Vila, M. (2003) The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann. N. Y. Acad. Sci., 991, 189-198.
39. Xiromerisiou, G., Kyratzi, E., Dardiotis, E., Bozi, M., Tsimourtou, V., Stamboulis, E., Ralli, S., Vassilatis, D., Gourbali, V., Kountra, P.M. et al. (2011) Lack of association of the UCHL-1 gene with Parkinson's disease in a Greek cohort: a haplotype-tagging approach. Mov. Disord. May 28. doi: 10.1002/mds.23694. [Epub ahead of print].
40. Bonifati, V., Rizzu, P., van Baren, M.J., Schaap, O., Breedveld, G.J., Krieger, E., Dekker, M.C., Squitieri, F., Ibanez, P., Joosse, M. et al. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science, 299, 256-259.
41. Hague, S., Rogaeva, E., Hernandez, D., Gulick, C., Singleton, A., Hanson, M., Johnson, J., Weiser, R., Gallardo, M., Ravina, B. et al. (2003) Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann. Neurol., 54, 271-274.
42. Hering, R., Strauss, K.M., Tao, X., Bauer, A., Woitalla, D., Mietz, E.M., Petrovic, S., Bauer, P., Schaible, W., Muller, T. et al. (2004) Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). Hum. Mutat., 24, 321-329.
43. Martinat, C., Shendelman, S., Jonason, A., Leete, T., Beal, M.F., Yang, L., Floss, T. and Abeliovich, A. (2004) Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES-derived cell model of primary Parkinsonism. PLoS Biol., 2, e327.
44. Simon-Sanchez, J., Schulte, C., Bras, J.M., Sharma, M., Gibbs, J.R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S.W., Hernandez, D.G. et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet., 41, 1308-1312.
45. Simon-Sanchez, J. and Singleton, A. (2008) Genome-wide association studies in neurological disorders. Lancet Neurol., 7, 1067-1072.
46. Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A. et al. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet., 41, 1303-1307.
47. Liu, Z., Meray, R.K., Grammatopoulos, T.N., Fredenburg, R.A., Cookson, M.R., Liu, Y., Logan, T. and Lansbury, P.T. Jr (2009) Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Proc. Natl Acad. Sci. USA, 106, 4635-4640.
48. Yamazaki, K., Wakasugi, N., Tomita, T., Kikuchi, T., Mukoyama, M. and Ando, K. (1988) Gracile axonal dystrophy (GAD), a new neurological mutant in the mouse. Proc. Soc. Exp. Biol. Med., 187, 209-215.
49. Sakurai, M., Sekiguchi, M., Zushida, K., Yamada, K., Nagamine, S., Kabuta, T. and Wada, K. (2008) Reduction in memory in passive avoidance learning, exploratory behaviour and synaptic plasticity in micewith a spontaneous deletion in the ubiquitin C-terminal hydrolase L1 gene. Eur. J. Neurosci., 27, 691-701.
50. Cartier, A.E., Djakovic, S.N., Salehi, A., Wilson, S.M., Masliah, E. and Patrick, G.N. (2009) Regulation of synaptic structure by ubiquitin C-terminal hydrolase L1. J. Neurosci., 29, 7857-7868.
51. Harada, T., Harada, C., Wang, Y.L., Osaka, H., Amanai, K., Tanaka, K., Takizawa, S., Setsuie, R., Sakurai, M., Sato, Y. et al. (2004) Role of ubiquitin carboxy terminal hydrolase-L1 in neural cell apoptosis induced by ischemic retinal injury in vivo. Am. J. Pathol., 164, 59-64.
52. Kwon, J., Wang, Y.L., Setsuie, R., Sekiguchi, S., Sato, Y., Sakurai, M., Noda, M., Aoki, S., Yoshikawa, Y. and Wada, K. (2004) Two closely related ubiquitin C-terminal hydrolase isozymes function as reciprocal modulators of germ cell apoptosis in cryptorchid testis. Am. J. Pathol., 165, 1367-1374.
53. Shen, H., Sikorska, M., Leblanc, J., Walker, P.R. and Liu, Q.Y. (2006) Oxidative stress regulated expression of ubiquitin carboxyl-terminal hydrolase-L1: role in cell survival. Apoptosis, 11, 1049-1059.
54. He, T.C., Zhou, S., da Costa, L.T., Yu, J., Kinzler, K.W. and Vogelstein, B. (1998) A simplified system for generating recombinant adenoviruses. Proc. Natl Acad. Sci. USA, 95, 2509-2514.
55. Jackson-Lewis, V. and Przedborski, S. (2007) Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc., 2, 141-151.
56. Pitychoutis, P.M., Nakamura, K., Tsonis, P.A. and Papadopoulou-Daifoti, Z. (2009) Neurochemical and behavioral alterations in an inflammatory model of depression: sex differences exposed. Neuroscience, 159, 1216-1232.
57. Franklin, K.B.J. and Paxinos, G. (2001) The Mouse Brain in Stereotaxic Coordinates, Academic press, San Diago.
58. Jackson-Lewis, V., Vila, M., Djaldetti, R., Guegan, C., Liberatore, G., Liu, J., O'Malley, K.L., Burke, R.E. and Przedborski, S. (2000) Developmental cell death in dopaminergic neurons of the substantia nigra of mice. J. Comp. Neurol., 424, 476-488.
59. Vila, M., Vukosavic, S., Jackson-Lewis, V., Neystat, M., Jakowec, M. and Przedborski, S. (2000) Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem., 74, 721-729.
60. Gundersen, H.J. and Jensen, E.B. (1987) The efficiency of systematic sampling in stereology and its prediction. J. Microsc., 147, 229-263.
61. Vogiatzi, T., Xilouri, M., Vekrellis, K. and Stefanis, L. (2008) Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J. Biol. Chem., 283, 23542-23556.
62. Stefanis, L., Park, D.S., Friedman, W.J. and Greene, L.A. (1999) Caspase-dependent and -independent death of camptothecin-treated embryonic cortical neurons. J. Neurosci., 19, 6235-6247.
63. Rideout, H.J. and Stefanis, L. (2002) Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination. Mol. Cell Neurosci., 21, 223-238.
64. Farinelli, S.E., Greene, L.A. and Friedman, W.J. (1998) Neuroprotective actions of dipyridamole on cultured CNS neurons. J. Neurosci., 18, 5112-5123.
65. Rukenstein, A., Rydel, R.E. and Greene, L.A. (1991) Multiple agents rescue PC12 cells from serum-free cell death by translation- and transcription-independent mechanisms. J. Neurosci., 11, 2552-2563.
66. Stefanis, L., Troy, C.M., Qi, H. and Greene, L.A. (1997) Inhibitors of trypsin-like serine proteases inhibit processing of the caspase Nedd-2 and protect PC12 cells and sympathetic neurons from death evoked by withdrawal of trophic support. J. Neurochem., 69, 1425-1437.